EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 25-32

  Fumoto, Shoichi ^a   Hiyama, Keiko ^a   Tanimoto, Keiji ^a   Noguchi, Takuya ^a   Hihara, Jun ^a   Hiyama, Eiso ^a   Noguchi, Tsuyoshi ^b   Nishiyama, Masahiko ^a,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

EMP3; Esophageal cancer; Prognosis; Telomerase; Tumor suppressor gene

Indexed keywords

HISTONE DEACETYLASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA CELL; CELL LINE; EMP3 GENE; ESOPHAGUS CARCINOMA; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASES; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM RECURRENCE, LOCAL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 57749090287     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.021     Document Type: Article

References (28)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24 (2006) 2137-2150
2. Pohl H., and Welch H.G. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97 (2005) 142-146
3. McCabe M.L., and Dlamini Z. The molecular mechanisms of oesophageal cancer. Int. Immunopharmacol. 5 (2005) 1113-1130
4. Kuwano H., Kato H., Miyazaki T., Fukuchi M., Masuda N., Nakajima M., Fukai Y., Sohda M., Kimura H., and Faried A. Genetic alterations in esophageal cancer. Surg. Today 35 (2005) 7-18
5. Egashira A., Morita M., Kakeji Y., Sadanaga N., Oki E., Honbo T., Ohta M., and Maehara Y. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. Cancer Sci. 98 (2007) 1152-1156
6. Sud N., Sharma R., Ray R., Chattopadhyay T.K., and Ralhan R. Differential expression of G-protein coupled receptor 56 in human esophageal squamous cell carcinoma. Cancer Lett. 233 (2006) 265-270
7. Nozoe T., Korenaga D., Futatsugi M., Saeki H., Maehara Y., and Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett. 192 (2003) 89-95
8. Heeren P., Plukker J., van Dullemen H., Nap R., and Hollema H. Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett. 225 (2005) 283-289
9. Yu H.P., Xu S.Q., Liu L., Shi L.Y., Cai X.K., Lu W.H., Lu B., Su Y.H., and Li Y.Y. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett. 198 (2003) 193-201
10. Vallböhmer D., and Lenz H.J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis. Esophagus 19 (2006) 425-432
11. Schrump D.S., and Nguyen D.M. Novel molecular targeted therapy for esophageal cancer. J. Surg. Oncol. 92 (2005) 257-261
12. Shimada H., Matsubara H., Shiratori T., Shimizu T., Miyazaki S., Okazumi S., Nabeya Y., Shuto K., Hayashi H., Tanizawa T., Nakatani Y., Nakasa H., Kitada M., and Ochiai T. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 97 (2006) 554-561
13. Ajani J.A. Carcinoma of the esophagus: is biology screaming in my deaf ears?. J. Clin. Oncol. 23 (2005) 4256-4258
14. Alaminos M., Davalos V., Ropero S., Setien F., Paz M.F., Herranz M., Fraga M.F., Mora J., Cheung N.K., Gerald W.L., and Esteller M. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 65 (2005) 2565-2571
15. Shimokuni T., Tanimoto K., Hiyama K., Otani K., Ohtaki M., Hihara J., Yoshida K., Noguchi T., Kawahara K., Natsugoe S., Aikou T., Okazaki Y., Hayashizaki Y., Sato Y., Todo S., Hiyama E., and Nishiyama M. Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. Int. J. Oncol. 28 (2006) 1153-1162
16. Kumazaki T., Hiyama K., Takahashi T., Omatsu H., Tanimoto K., Noguchi T., Hiyama E., Mitsui Y., and Nishiyama M. Differential gene expressions during immortalization of normal human fibroblasts and endothelial cells transfected with human telomerase reverse transcriptase gene. Int. J. Oncol. 24 (2004) 1435-1442
17. Tanaka T., Tanimoto K., Otani K., Satoh K., Ohtaki M., Yoshida K., Toge T., Yahata H., Tanaka S., Chayama K., Okazaki Y., Hayashizaki Y., Hiyama K., and Nishiyama M. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int. J. Cancer 111 (2004) 617-626
18. Tanimoto K., Yoshiga K., Eguchi H., Kaneyasu M., Ukon K., Kumazaki T., Oue N., Yasui W., Imai K., Nakachi K., Poellinger L., and Nishiyama M. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24 (2003) 1779-1783
19. Taylor V., and Suter U. Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene 175 (1996) 115-120
20. Wilson H.L., Wilson S.A., Surprenant A., and North R.A. Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J. Biol. Chem. 277 (2002) 34017-34023
21. Hiyama K., Hiyama E., Ishioka S., Yamakido M., Inai K., Gazdar A.F., Piatyszek M.A., and Shay J.W. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87 (1995) 895-902
22. Hiyama E., Gollahon L., Kataoka T., Kuroi K., Yokoyama T., Gazdar A.F., Hiyama K., Piatyszek M.A., and Shay J.W. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88 (1996) 116-122
23. Collins K. The biogenesis and regulation of telomerase holoenzymes. Nat. Rev. Mol. Cell Biol. 7 (2006) 484-494
24. Horikawa I., and Barrett J.C. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24 (2003) 1167-1176
25. Sato F., and Meltzer S.J. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106 (2006) 483-493
26. Burmester J.K., Suarez B.K., Lin J.H., Jin C.H., Miller R.D., Zhang K.Q., Salzman S.A., Reding D.J., and Catalona W.J. Analysis of candidate genes for prostate cancer. Hum. Hered. 57 (2004) 172-178
27. Kunitz A., Wolter M., van den Boom J., Felsberg J., Tews B., Hahn M., Benner A., Sabel M., Lichter P., Reifenberger G., von Deimling A., and Hartmann C. DNA hypermethylation and Aberrant Expression of the EMP3 Gene at 19q13.3 in Human Gliomas. Brain Pathol. 17 (2007) 363-370
28. Li K.K., Pang J.C., Chung N.Y., Ng Y.L., Chan N.H., Zhou L., Poon W.S., and Ng H.K. EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. Int. J. Cancer 120 (2007) 947-950